Trial Profile
Prospective, randomized trial of basiliximab (Simulect) in the prophylaxis of high-risk keratoplasty patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2013
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Ciclosporin
- Indications Keratoplasty rejection
- Focus Therapeutic Use
- 28 Dec 2006 New trial record.